Armata Pharmaceuticals (ARMP) News Today → Exposed: 10 CENT Crypto to Explode May 20th? (From True Market Insiders) (Ad) Free ARMP Stock Alerts $3.20 +0.11 (+3.56%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 2:55 AM | americanbankingnews.comArmata Pharmaceuticals, Inc. to Post Q2 2024 Earnings of ($0.52) Per Share, HC Wainwright Forecasts (NYSEAMERICAN:ARMP)May 10 at 4:46 AM | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Armata Pharmaceuticals (NYSEAMERICAN:ARMP)May 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Armata Pharmaceuticals Amid Progress and Strategic Financial MovesMay 8, 2024 | marketbeat.comArmata Pharmaceuticals' (ARMP) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and issued a $7.00 target price on shares of Armata Pharmaceuticals in a research note on Wednesday.May 8, 2024 | finanznachrichten.deArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate UpdateMay 8, 2024 | americanbankingnews.comArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading 13.9% Higher May 8, 2024 | investorplace.comARMP Stock Earnings: Armata Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024May 7, 2024 | finance.yahoo.comArmata Pharmaceuticals Q1 2024 Earnings: Narrower Losses and Strategic AdvancesMay 7, 2024 | prnewswire.comArmata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate UpdateApril 13, 2024 | marketbeat.comArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading Down 1.8%Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Down 1.8%March 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Armata Pharmaceuticals Amid Progress in Bacteriophage Therapy DevelopmentMarch 23, 2024 | finance.yahoo.comArmata Pharmaceuticals Inc (ARMP) Earnings: Navigates Through R&D to Narrow LossesMarch 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Armata Pharmaceuticals Amid Clinical Progress and Strategic GrowthMarch 22, 2024 | marketbeat.comArmata Pharmaceuticals (NYSEAMERICAN:ARMP) Rating Reiterated by HC WainwrightHC Wainwright restated a "buy" rating and issued a $7.00 price objective on shares of Armata Pharmaceuticals in a research report on Friday.March 22, 2024 | finanznachrichten.deArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate UpdateMarch 21, 2024 | finance.yahoo.comArmata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate UpdateMarch 15, 2024 | finance.yahoo.comINVA Apr 2024 15.000 callMarch 13, 2024 | marketbeat.comArmata Pharmaceuticals (ARMP) to Release Earnings on ThursdayArmata Pharmaceuticals (NYSEAMERICAN:ARMP) will be releasing earnings on Thursday, March 14, Yahoo Finance reports.March 10, 2024 | finance.yahoo.comINVA Mar 2024 7.500 callMarch 6, 2024 | investing.comArmata secures $35 million to fund phage therapy trialsMarch 5, 2024 | marketbeat.comArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Sees Large Decrease in Short InterestArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) was the recipient of a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 43,500 shares, a decline of 5.2% from the January 31st total of 45,900 shares. Based on an average daily volume of 18,500 shares, the days-to-cover ratio is presently 2.4 days. Approximately 0.4% of the shares of the company are sold short.March 4, 2024 | finance.yahoo.comArmata Pharmaceuticals Announces $35 Million Secured Credit Agreement with InnovivaFebruary 21, 2024 | finance.yahoo.comArmata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy SummitFebruary 21, 2024 | prnewswire.comArmata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy SummitFebruary 14, 2024 | marketbeat.comShort Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Drops By 17.9%Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) saw a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 45,900 shares, a decline of 17.9% from the January 15th total of 55,900 shares. Currently, 0.4% of the company's shares are sold short. Based on an average daily trading volume, of 17,900 shares, the short-interest ratio is currently 2.6 days.February 10, 2024 | investing.comArmata Pharmaceuticals Inc (ARMP)February 2, 2024 | morningstar.comArmata Pharmaceuticals Inc ARMPJanuary 3, 2024 | marketbeat.comShort Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Rises By 9.4%Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 99,100 shares, a growth of 9.4% from the November 30th total of 90,600 shares. Currently, 0.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 14,000 shares, the short-interest ratio is presently 7.1 days.November 15, 2023 | markets.businessinsider.comRobust Advancements and Strategic Planning: Key Drivers for Armata Pharmaceuticals’ Buy RatingNovember 15, 2023 | finance.yahoo.comArmata Pharmaceuticals Inc (ARMP) Reports Q3 2023 Financial Results and Corporate UpdatesNovember 15, 2023 | finanznachrichten.deArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate UpdateNovember 14, 2023 | finance.yahoo.comArmata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate UpdateNovember 6, 2023 | money.usnews.comLexeo Therapeutics Inc.October 30, 2023 | finance.yahoo.comArmata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis ConferenceOctober 19, 2023 | finance.yahoo.comArmata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023October 4, 2023 | msn.comArmata Pharmaceuticals (ARMP) Price Target Increased by 14.29% to 8.16September 28, 2023 | markets.businessinsider.comArmata Pharmaceuticals: Promising Clinical Trials and New Leadership Bolster Buy RecommendationSeptember 26, 2023 | finance.yahoo.comArmata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureusSeptember 21, 2023 | finance.yahoo.comArmata Pharmaceuticals to Participate in the Cantor Global Healthcare ConferenceAugust 22, 2023 | uk.news.yahoo.comArmata Pharma (ARMP) Stock Surges 130% in a Month: Here's WhyAugust 17, 2023 | finance.yahoo.comArmata Pharmaceuticals, Inc. (ARMP) Now Trades Above Golden Cross: Time to Buy?August 15, 2023 | markets.businessinsider.comLadenburg Thalmann & Co. Reaffirms Their Buy Rating on Armata Pharmaceuticals (ARMP)August 14, 2023 | finanznachrichten.deArmata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate UpdateAugust 14, 2023 | seekingalpha.comArmata Pharmaceuticals GAAP EPS of -$0.17, revenue of $0.98MAugust 14, 2023 | finance.yahoo.comArmata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate UpdateAugust 14, 2023 | finance.yahoo.comARMP - Armata Pharmaceuticals, Inc.July 24, 2023 | benzinga.comDow Surges 150 Points; Domino's Pizza Earnings Top ExpectationsJuly 11, 2023 | msn.comArmata Pharmaceuticals gets $25M in financing and new executive chiefMay 31, 2023 | finance.yahoo.comArmata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage TherapyMay 12, 2023 | msn.comHC Wainwright & Co. Reiterates Armata Pharmaceuticals (ARMP) Buy Recommendation Get Armata Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARMP and its competitors with MarketBeat's FREE daily newsletter. Email Address He Is Giving Away Bitcoin (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin. >> Register right here ARMP Media Mentions By Week ARMP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARMP News Sentiment▼-0.540.58▲Average Medical News Sentiment ARMP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARMP Articles This Week▼141▲ARMP Articles Average Week Get Armata Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARMP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Xtant Medical News Today Outlook Therapeutics News Today Gritstone bio News Today Passage Bio News Today bluebird bio News Today Curis News Today Sangamo Therapeutics News Today AlloVir News Today CEL-SCI News Today aTyr Pharma News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:ARMP) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Armata Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
